KYNB Kyntra Bio, Inc.
Healthcare$6.99+0.72%ClosedMarket Cap: $28.3M
As of 2026-05-25
Valuation
P/E (TTM)
0.16
PEG
0.00
P/B
-3.05
P/S
3.80
EV/EBITDA
0.19
DCF Value
$11.13
FCF Yield
-75.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.7%
Operating Margin
-596.2%
Net Margin
1498.0%
ROE
-182.1%
ROA
101.7%
ROIC
-54.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.7M | 0.0% | $-13.8M | $-15.2M | $— | — |
| Q4 null | $1.3M | 0.0% | $-13.5M | $-14.2M | $— | — |
| FY null | $6.4M | 0.0% | $-45.9M | $183.5M | $— | — |
| Q3 null | $1.1M | 87.5% | $-5.4M | $148.5M | $— | — |
| Q2 null | $1.3M | 77.3% | $-11.7M | $-7.6M | $— | — |
| Q1 null | $2.7M | 78.9% | $-14.8M | $4.6M | $— | — |
| Q4 null | $-123.3M | 83.2% | $-91.7M | $18.0M | $— | — |
| FY null | $29.6M | 47.5% | $-150.4M | $-47.6M | $— | — |
| Q3 null | $46.3M | 88.6% | $-16.8M | $-17.1M | $— | — |
| Q2 null | $998.0K | -3156.5% | $-46.4M | $-15.5M | $— | — |
| Q1 null | $25.4M | -128.0% | $-49.2M | $-32.9M | $— | — |
| Q4 2023 | $27.1M | 80.1% | $-54.2M | $-56.2M | $-0.57 | — |